Clinical trial
Prospective Clinical Validation of an Artificial Intelligence System for Biliary Tract Cancer Screening Using Non-Contrast Computed Tomography
NCT07911397 is registered in ClinicalTrials.gov with Beijing Tsinghua Chang Gung Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started October 2026. Interventional study, 10,000 participants (estimated). Lead sponsor Beijing Tsinghua Chang Gung Hospital; China. Primary measure: Patient-level area under the receiver operating characteristic curve (AUC) of the AI system...
How it compares
53 similar trials: same condition (Biliary Tract Neoplasms) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Clinical Validation of an Artificial Intelligence System for Biliary Tract Cancer Screening Using Non-Contrast Computed Tomography
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- October 1, 2026
- Completion date
- February 28, 2027
- Enrollment
- 10,000 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: biliary tract cancer (btc)
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- Yes
- Study type
- Interventional
- Sites
- 1
- Countries
- China
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
Arms
As registered; 1 arm.
| Arm | Type | Interventions |
|---|---|---|
| AI-Assisted NCCT Screening | Experimental | AI-Assisted Biliary Tract Cancer Screening Using NCCT |
Show registry wordingParticipants in this arm will undergo AI-assisted screening for biliary tract cancer using non-contrast computed tomography (NCCT). The artificial intelligence system will independently analyze eligible NCCT examinations and generate a patient-level risk score for biliary tract cancer. The AI output will be evaluated against a predefined clinical reference standard. Routine clinical interpretation and patient management will not be replaced by the AI system. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Patient-level area under the receiver operating characteristic curve (AUC) of the AI system for distinguishing biliary tract cancer from non-biliary-tract-cancer cases using non-contrast computed tomography (NCCT) | From the index NCCT examination to completion of the reference standard assessment, up to 30 days |
Show registry wordingThe primary outcome is the patient-level area under the receiver operating characteristic curve (AUC) for the AI system in distinguishing biliary tract cancer from non-biliary-tract-cancer cases using non-contrast computed tomography (NCCT). Biliary tract cancer includes intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, distal cholangiocarcinoma, and gallbladder cancer. The reference diagnosis will be established using the predefined clinical reference standard. | |
Lead sponsor's other trials
Beijing Tsinghua Chang Gung Hospital, most recent start first.
+104 more trials See the organization page
Similar trials
Same condition (Biliary Tract Neoplasms) and phase, most recent start first.
+48 more trials See the condition page